HedgeChatter

  • Home /
  • Tag Archives

HEB

Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2014

[GlobeNewswire] – PHILADELPHIA — Hemispherx Biopharma (NYSE MKT:HEB) announced its financial results for the three months ended March 31, 2014. The net loss (including non-cash effects) was approximately $3,836,000 or … moreView todays social media effects on HEBView the latest stocks trending across Twitter. Click to view dashboardSee who Hemispherx is hiring next, click here to view […]

May 9, 2014 Bystocknews , Comments Off on Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2014 read more

8:32 am Hemispherx Biopharma announced that one of its advanced stage biological products, Alferon N, significantly inhibited the replication of the MERS virus in vitro

moreView todays social media effects on HEBView the latest stocks trending across Twitter. Click to view dashboardSee who Hemispherx is hiring next, click here to view […]

May 5, 2014 Bystocknews , Comments Off on 8:32 am Hemispherx Biopharma announced that one of its advanced stage biological products, Alferon N, significantly inhibited the replication of the MERS virus in vitro read more

Alferon(R) N Effective Against MERS (Middle East Respiratory Syndrome) Virus In-Vitro

[GlobeNewswire] – PHILADELPHIA — Hemispherx Biopharma (NYSE MKT:HEB) announced that one of its advanced stage biological products, Alferon(R) N, significantly inhibited the replication of the MERS virus in vitro. MERS-CoV … moreView todays social media effects on HEBView the latest stocks trending across Twitter. Click to view dashboardSee who Hemispherx is hiring next, click here to view […]

May 5, 2014 Bystocknews , Comments Off on Alferon(R) N Effective Against MERS (Middle East Respiratory Syndrome) Virus In-Vitro read more

8:34 am Hemispherx Biopharma announces new publication enlarges the understanding of ampligen safety profile across diverse animal species and Focuses on the unique TLR-3 receptor/ampligen interaction

moreView todays social media effects on HEBView the latest stocks trending across Twitter. Click to view dashboardSee who Hemispherx is hiring next, click here to view […]

April 9, 2014 Bystocknews , Comments Off on 8:34 am Hemispherx Biopharma announces new publication enlarges the understanding of ampligen safety profile across diverse animal species and Focuses on the unique TLR-3 receptor/ampligen interaction read more

8:33 am Hemispherx Biopharma Presented Clinical Interpretations on CFS Treatment; Dichotomization of improvement in exercise performance from baseline at the 25% and 50% levels were analyzed on the Intent-to-Treat Population

moreView todays social media effects on HEBView the latest stocks trending across Twitter. Click to view dashboardSee who Hemispherx is hiring next, click here to view […]

March 25, 2014 Bystocknews , Comments Off on 8:33 am Hemispherx Biopharma Presented Clinical Interpretations on CFS Treatment; Dichotomization of improvement in exercise performance from baseline at the 25% and 50% levels were analyzed on the Intent-to-Treat Population read more

11:01 am Hemispherx Biopharma plans to file for regulatory approval of Ampligen to treat Chronic Fatigue Syndrome in three additional Latin American countries

moreView todays social media effects on HEBView the latest stocks trending across Twitter. Click to view dashboardSee who Hemispherx is hiring next, click here to view […]

March 11, 2014 Bystocknews , Comments Off on 11:01 am Hemispherx Biopharma plans to file for regulatory approval of Ampligen to treat Chronic Fatigue Syndrome in three additional Latin American countries read more

Hemispherx Biopharma Publishes Full National Press Club Presentation on Corporate Website …Overview of Clinical Programs Directed Towards Development of Universal Pandemic Influenza Vaccine

[at noodls] – Hemispherx Biopharma Publishes Full National Press Club Presentation on Corporate Website …Overview of Clinical Programs Directed Towards Development of Universal Pandemic Influenza Vaccine Philadelphia, … moreView todays social media effects on HEBView the latest stocks trending across Twitter. Click to view dashboardSee who Hemispherx is hiring next, click here to view […]

February 24, 2014 Bystocknews , Comments Off on Hemispherx Biopharma Publishes Full National Press Club Presentation on Corporate Website …Overview of Clinical Programs Directed Towards Development of Universal Pandemic Influenza Vaccine read more

8:35 am Hemispherx Biopharma will publish full National Press Club Presentation on Corporate Website; Overview of clinical programs directed towards development of Universal Pandemic Influenza Vaccine

moreView todays social media effects on HEBView the latest stocks trending across Twitter. Click to view dashboardSee who Hemispherx is hiring next, click here to view […]

February 24, 2014 Bystocknews , Comments Off on 8:35 am Hemispherx Biopharma will publish full National Press Club Presentation on Corporate Website; Overview of clinical programs directed towards development of Universal Pandemic Influenza Vaccine read more

Hemispherx Biopharma Publishes Full National Press Club Presentation on Corporate Website

[GlobeNewswire] – PHILADELPHIA — Hemispherx Biopharma (NYSE MKT:HEB) announced today that the full text of the Hemispherx presentation given at the National Press Club (NPC) Conference in Washington, DC, on January 30, … moreView todays social media effects on HEBView the latest stocks trending across Twitter. Click to view dashboardSee who Hemispherx is hiring next, click here to view […]

February 24, 2014 Bystocknews , Comments Off on Hemispherx Biopharma Publishes Full National Press Club Presentation on Corporate Website read more